Multiple myeloma may be the second most common hematologic malignancy. in
Multiple myeloma may be the second most common hematologic malignancy. in the transplant and not-transplant settings. In particular this paper will present an overview of the results accomplished with lenalidomide-containing mixtures in patients eligible for high-dose Vincristine sulfate therapies namely young patients. The advantages obtained should always Vincristine sulfate be outweighed with the toxicity profile … [Read more…]